Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 20/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | BPTF | Q12830 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 12/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 12/20 | 0.39 |
| ▸ | BCHE | P06276 | 12/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22019991 | 0.81 | KMT2A (0.33) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL21963362 | 0.81 | ACHE (0.46) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL21963168 | 0.79 | ACHE (0.43) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL21963121 | 0.78 | ACHE (0.42) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL21963238 | 0.78 | ACHE (0.42) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL21963338 | 0.76 | ACHE (0.50) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL22020056 | 0.72 | KMT2A (0.36) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL21963227 | 0.69 | ACHE (0.55) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL21963425 | 0.69 | ACHE (0.50) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL30162186 | 0.67 | ACHE (0.39) | ACHEMEN1MAPK1KMT2ABPTF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667054-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| EP-3880660-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-02 | — | — | US | disclosed |
| EP-3880660-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| CN-113166065-A | Compounds and compositions for treating conditions associated with NLRP activity | 诺华股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020102096-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020102096-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | ACHE 4177/4885MEN1 3390/4885MAPK1 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.